Pharma BD Deal Intelligence
Mallinckrodt expands its hospital growth platform with the $1.325B Therakos acquisition, broadening exposure to immunotherapy and recurring photopheresis…
The acquisition closes, adding Therakos's global photopheresis franchise and expected $185-195M in FY2015 sales to Mallinckrodt's specialty hospital portfolio.
Nine years after paying $1.325B, Mallinckrodt sold Therakos to CVC for $925M to reduce net debt by over 60%, suggesting the original acquisition price did not…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Mallinckrodt acquired Therakos from The Gores Group for approximately $1.325B, adding the global leader in autologous immune cell therapy via extracorporeal photopheresis. Closed September 28, 2015. Mallinckrodt later divested Therakos to CVC Capital for $925M (2021).
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mallinckrodt plc / Therakos, Inc. (this deal) | 2015 | $1.3B | 48 |
| Mallinckrodt plc / Cadence Pharmaceuticals, Inc. | 2014 | $1.4B | 50 |
| Mallinckrodt plc / Ikaria, Inc. | 2015 | $2.3B | 37 |
| Mallinckrodt plc / Sucampo Pharmaceuticals, Inc. | 2017 | $1.2B | 19 |
| Mallinckrodt plc / Questcor Pharmaceuticals, Inc. | 2014 | $5.6B | 18 |
| Mallinckrodt plc / InfaCare Pharmaceutical Corporation | 2017 | $425M | 12 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
← Browse all deals · How we score deals
More: 2015 deals · Mallinckrodt plc deals · Hematology deals